- Home
- BLLN vs NAMS Comparison
BLLN vs NAMS Comparison
Compare BLLN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLLN | NAMS |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.0B |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | BLLN | NAMS |
|---|---|---|
| Price | $87.17 | $31.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $137.83 | $46.40 |
| AVG Volume (30 Days) | 259.9K | ★ 764.0K |
| Earning Date | 12-09-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $254,136,000.00 | $35,243,000.00 |
| Revenue This Year | $98.01 | N/A |
| Revenue Next Year | $35.84 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 254.30 | 4.91 |
| 52 Week Low | $80.51 | $14.06 |
| 52 Week High | $138.70 | $42.00 |
Technical Indicators
Market Signals| Indicator | BLLN | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 35.61 |
| Support Level | N/A | $30.97 |
| Resistance Level | N/A | $32.45 |
| Average True Range (ATR) | 0.00 | 1.61 |
| MACD | 0.00 | -0.29 |
| Stochastic Oscillator | 0.00 | 11.40 |
Price Performance
Historical ComparisonAbout BLLN BillionToOne Inc.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.